TORONTO and CHICAGO, April 18, 2023 Medexus Pharmaceuticals is pleased to announce that company management will be participating in the 2023 Bloom Burton & Co. Healthcare Investor. | April 18, 2023
Annual revenue expected to exceed US$107 million for fiscal year ended March 31, 2023, an all-time record, including fiscal Q4 2023 revenue of at least US$28 millionTORONTO and CHICAGO, April 11,. | April 11, 2023
Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to. | August 8, 2022